429 Human tumor response to a standard monotherapy checkpoint inhibitor in a humanized HSC-NCG mouse model engrafting adult healthy donor-mobilized human CD34+ hematopoietic stem cells

Abstract

BackgroundCheckpoint inhibitors, including those of the PD-1/PD-L1 pathway, are immunotherapies used for the standard of care for cancer patients. New treatments or immunotherapies are compared to those that are currently...